RCUS

Arcus Biosciences, Inc. NYSE

Healthcare ·Biotechnology ·US · arcusbio.com

$26.05

Mkt Cap $2.6B

52w Low $7.06 87.7% of range 52w High $28.72

50d MA $22.61 200d MA $18.57

P/E (TTM) -7.8x

EV/EBITDA -7.3x

P/B 4.4x

Debt/Equity 0.2x

ROE -55.9%

P/FCF -5.3x

RSI (14) —

ATR (14) —

Beta 0.86

50d MA $22.61

200d MA $18.57

Avg Volume 1.2M

About

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	-1.11	-0.89	+19.8%	20.27	-1.9%	-3.6%	+0.5%	+18.1%	+10.7%	+11.9%	—
Oct 28, 2025	AMC	-1.33	-1.27	+4.5%	19.88	+0.6%	+2.1%	+1.6%	-0.8%	+2.4%	-0.3%	—
Aug 6, 2025	AMC	-1.14	-0.08	+93.4%	9.49	+5.1%	-2.2%	-4.5%	-3.5%	+1.9%	+6.0%	—
May 6, 2025	AMC	-1.02	-1.14	-11.8%	8.12	-8.4%	-1.4%	+5.0%	+2.0%	+8.4%	+6.8%	—
Feb 25, 2025	AMC	-1.17	-1.03	+12.0%	10.24	+13.2%	-1.0%	-3.5%	+6.3%	+2.5%	-5.4%	—
Nov 6, 2024	AMC	-1.07	-1.00	+6.5%	15.73	+2.5%	+4.6%	+13.5%	+12.8%	+6.6%	+4.5%	—
Aug 8, 2024	AMC	-1.02	-1.02	+0.0%	13.69	+8.8%	+14.0%	+9.2%	+14.2%	+7.0%	+14.9%	—
May 8, 2024	AMC	-0.97	-0.05	+94.8%	15.26	+11.1%	+5.8%	+9.5%	+12.8%	+12.1%	+15.0%	—
Feb 21, 2024	AMC	-1.09	-1.08	+0.9%	16.41	+3.6%	+19.9%	+19.0%	+19.8%	+23.0%	+16.7%	—
Nov 7, 2023	AMC	-1.12	-0.94	+16.1%	16.45	+0.5%	-2.7%	-16.5%	-17.7%	-18.4%	-12.5%	—
Aug 7, 2023	AMC	-1.00	-1.04	-4.0%	18.21	-0.8%	+1.3%	-0.9%	+1.3%	+0.0%	-1.0%	—
May 9, 2023	AMC	-1.06	-1.09	-2.8%	19.40	-0.7%	-3.0%	-7.1%	-4.7%	+0.6%	-5.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 2	Wedbush	Maintains	Outperform → Outperform	—	$21.84	$21.95	+0.5%	+5.1%	+1.8%	+1.1%	+3.7%	+6.6%
Mar 5	Citigroup	Maintains	Buy → Buy	—	$22.68	$22.39	-1.3%	-2.1%	-2.5%	+3.3%	+8.3%	+7.7%
Mar 2	Leerink Partners	Maintains	Outperform → Outperform	—	$20.37	$20.47	+0.5%	+17.5%	+10.1%	+11.3%	+9.0%	+8.5%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.37	$20.47	+0.5%	+17.5%	+10.1%	+11.3%	+9.0%	+8.5%
Feb 12	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$21.36	$21.58	+1.0%	-6.6%	-11.4%	-9.9%	-9.0%	-8.8%
Jan 13	Goldman Sachs	Upgrade	Neutral → Buy	—	$21.30	$22.19	+4.2%	+6.8%	+15.3%	+2.3%	+2.3%	+3.1%
Jan 8	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$23.20	$22.14	-4.6%	-8.0%	-9.4%	-8.2%	-2.0%	+5.9%
Dec 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.14	$21.15	-15.9%	-14.4%	-12.8%	-11.7%	-11.4%	-12.5%
Nov 28	BofA Securities	Maintains	Neutral → Neutral	—	$25.56	$25.81	+1.0%	+2.1%	+2.1%	-0.5%	+0.3%	-1.2%
Oct 30	Goldman Sachs	Maintains	Neutral → Neutral	—	$20.29	$20.00	-1.4%	-0.5%	-2.8%	+0.3%	-2.3%	-2.7%
Oct 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.88	$20.00	+0.6%	+2.1%	+1.6%	-0.8%	+2.4%	-0.3%
Oct 29	Citigroup	Maintains	Buy → Buy	—	$19.88	$20.00	+0.6%	+2.1%	+1.6%	-0.8%	+2.4%	-0.3%
Oct 20	Wells Fargo	Maintains	Overweight → Overweight	—	$16.47	$16.66	+1.2%	+6.1%	+9.6%	+2.0%	+1.9%	+5.1%
Oct 13	Citigroup	Maintains	Buy → Buy	—	$14.60	$15.80	+8.2%	+14.0%	+7.0%	+15.8%	+13.7%	+12.8%
Oct 7	Truist	Maintains	Buy → Buy	—	$14.48	$14.78	+2.1%	-3.1%	+3.9%	+4.7%	+0.8%	+14.9%
Aug 7	Morgan Stanley	Maintains	Overweight → Overweight	—	$9.49	$9.97	+5.1%	-2.2%	-4.5%	-3.5%	+1.9%	+6.0%
Aug 7	Wells Fargo	Maintains	Overweight → Overweight	—	$9.49	$9.97	+5.1%	-2.2%	-4.5%	-3.5%	+1.9%	+6.0%
May 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$8.53	$8.46	-0.8%	-2.9%	+3.2%	+1.6%	+0.1%	+0.5%
May 8	Goldman Sachs	Maintains	Neutral → Neutral	—	$8.01	$7.96	-0.6%	+6.5%	+3.4%	+9.9%	+8.2%	+6.6%
May 7	Wells Fargo	Maintains	Overweight → Overweight	—	$8.12	$7.44	-8.4%	-1.4%	+5.0%	+2.0%	+8.4%	+6.8%
Apr 23	Barclays	Maintains	Overweight → Overweight	—	$8.09	$8.21	+1.5%	+0.2%	+4.0%	+2.6%	+2.0%	+0.5%
Feb 26	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$10.24	$11.59	+13.2%	-1.0%	-3.5%	+6.3%	+2.5%	-5.4%
Feb 19	BofA Securities	Maintains	Neutral → Neutral	—	$10.96	$11.17	+1.9%	+1.3%	-2.0%	+1.0%	-7.3%	-6.6%
Feb 18	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$13.10	$12.80	-2.3%	-16.3%	-15.3%	-18.0%	-15.5%	-22.4%
Feb 18	Morgan Stanley	Maintains	Overweight → Overweight	—	$13.10	$12.80	-2.3%	-16.3%	-15.3%	-18.0%	-15.5%	-22.4%
Nov 6	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$15.29	$16.23	+6.1%	+2.9%	+7.7%	+16.7%	+16.1%	+9.7%
Oct 25	Barclays	Maintains	Overweight → Overweight	—	$17.83	$18.15	+1.8%	-8.5%	-6.6%	-8.0%	-10.3%	-14.2%
Oct 24	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$17.33	$17.91	+3.3%	+2.9%	-5.8%	-3.9%	-5.3%	-7.7%
Oct 3	Wedbush	Maintains	Outperform → Outperform	—	$15.39	$15.19	-1.3%	-0.5%	+8.2%	+12.4%	+13.5%	+15.3%
Aug 9	Wedbush	Maintains	Outperform → Outperform	—	$13.69	$14.90	+8.8%	+14.0%	+9.2%	+14.2%	+7.0%	+14.9%
Aug 9	BofA Securities	Maintains	Neutral → Neutral	—	$13.69	$14.90	+8.8%	+14.0%	+9.2%	+14.2%	+7.0%	+14.9%
Jul 8	Barclays	Maintains	Overweight → Overweight	—	$14.12	$14.19	+0.5%	-2.0%	-0.3%	-1.3%	+5.7%	+7.0%
Jun 24	Truist	Maintains	Buy → Buy	—	$16.35	$16.50	+0.9%	+0.4%	-3.2%	-7.3%	-7.2%	-6.9%
Jun 3	Citigroup	Maintains	Buy → Buy	—	$15.07	$15.82	+5.0%	+5.1%	+6.2%	+8.0%	+5.5%	+2.9%
May 13	Morgan Stanley	Maintains	Overweight → Overweight	—	$16.71	$17.00	+1.7%	+3.0%	+2.4%	+5.0%	+4.5%	+1.1%
May 9	Wedbush	Maintains	Outperform → Outperform	—	$15.26	$16.96	+11.1%	+5.8%	+9.5%	+12.8%	+12.1%	+15.0%
Mar 25	Truist	Maintains	Buy → Buy	—	$16.43	$16.47	+0.2%	+0.2%	+1.3%	+10.8%	+14.9%	+12.5%
Feb 22	Wedbush	Maintains	Outperform → Outperform	—	$16.41	$17.00	+3.6%	+19.9%	+19.0%	+19.8%	+23.0%	+16.7%
Jan 30	Wedbush	Maintains	Outperform → Outperform	—	$15.30	$16.11	+5.3%	+2.7%	-1.0%	+3.6%	-2.2%	-0.5%
Jan 30	Mizuho	Maintains	Buy → Buy	—	$15.30	$16.11	+5.3%	+2.7%	-1.0%	+3.6%	-2.2%	-0.5%
Jan 17	Wedbush	Maintains	Outperform → Outperform	—	$16.90	$16.82	-0.5%	+0.6%	-3.1%	-9.2%	-10.6%	-8.6%
Nov 13	Morgan Stanley	Maintains	Overweight → Overweight	—	$13.54	$13.38	-1.2%	-0.8%	+6.3%	+7.5%	+3.8%	+7.0%
Nov 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$16.45	$16.54	+0.5%	-2.7%	-16.5%	-17.7%	-18.4%	-12.5%
Oct 3	Mizuho	Maintains	Buy → Buy	—	$17.29	$17.24	-0.3%	-1.3%	-8.5%	-5.3%	-3.4%	-5.1%
Sep 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$20.79	$20.54	-1.2%	+2.2%	-0.3%	-2.6%	-1.1%	-4.3%
Sep 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$22.50	$22.39	-0.5%	-5.4%	-5.0%	-7.6%	-5.6%	-7.9%
Sep 6	Truist	Maintains	Buy → Buy	—	$21.99	$22.19	+0.9%	+2.3%	-3.2%	-2.8%	-5.5%	-3.4%
Sep 5	BofA Securities	Maintains	Neutral → Neutral	—	$21.20	$21.00	-0.9%	+3.7%	+6.1%	+0.4%	+0.8%	-1.9%
Aug 24	Citigroup	Maintains	Buy → Buy	—	$23.03	$23.00	-0.1%	-0.5%	-1.9%	-5.5%	-12.4%	-12.8%
Aug 23	Mizuho	Maintains	Buy → Buy	—	$18.81	$23.22	+23.4%	+22.4%	+21.9%	+20.1%	+15.7%	+7.3%

Recent Filings

8-K · 8.01 !! High

Arcus Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement

Gilead's acquisition of Arcus Biosciences faces setback as the STAR-121 trial of domvanalimab and zimberelimab failed to meet futility analysis criteria for first-line lung cancer treatment.

Apr 20

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

# Analysis: RCUS Executive Change Rcus's executive departure increases uncertainty about strategic direction and operational continuity, potentially pressuring the stock until management stability is demonstrated and a replacement plan is announced.

Mar 23

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

A life sciences-focused executive with deep investment banking expertise joined one of these companies, potentially signaling strategic M&A activity or capital-raising plans ahead.

Mar 23

8-K

Arcus Biosciences, Inc. -- 8-K Filing

Arcus Biosciences reported 2025 financial results and shared updated ASCO GU data supporting casdatifan's potential as a best-in-class HIF-2α inhibitor for cancer treatment.

Feb 25

Data updated apr 26, 2026 10:08pm · Source: massive.com